Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...

Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...

Objectives To evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still’s ...

Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...

Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...

Over the last decade, the outlook for patients with rheumatoid arthritis (RA) has improved, but there is growing interest in ...

Objectives Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and ...

Objectives To identify glucocorticoid (GC) treatment patterns in patients with polymyalgia rheumatica (PMR) and explore patient profiles that may benefit from GC-sparing interventions. Methods This ...

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by the presence of autoantibodies. Their value for diagnostic/prognostic purposes has been well established. In contrast, their ...

Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial ...

Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) ...